Skip to main content
  • About Us
  • Image Credits
  • Contributor Info
  • RSS
  • Log In
  • Join
  • TwitterTwitter
  • E-Alerts
  • Visit StemJournal

Main menu

  • About
    • Image Credits
    • Contributor Info
    • E-Alerts
  • Chapters
    • Cellular and nuclear reprogramming
    • Ectoderm specification and differentiation
    • Endoderm specification and differentiation
    • Epigenetics
    • Genomics and proteomics
    • Germ cell and somatic stem cell biology in reproduction
    • Manufacturing
    • Mesoderm specification and differentiation
    • Niche biology, homing, and migration
    • Renewal
    • Stem cell immunology
    • Therapeutic prospects
    • Tissue engineering
  • Protocols
    • Ectoderm differentiation
    • Endoderm differentiation
    • Genome editing
    • Mesoderm differentiation
    • Pluripotent stem cells
    • PSC characterization
    • PSC genetic stability
    • Reprogramming
  • Stem Cell COREdinates
    • Core Facility Profiles
      • Boston Children's Hospital Human Neuron Core
      • Boston University Center for Regenerative Medicine iPSC Core
      • Columbia Stem Cell Initiative Stem Cell Core Facility
      • Harvard Stem Cell Institute iPS Core Facility
    • Other Resources
  • News & Commentaries
    • Latest News
  • Journal Stream
  • Forum

    Search form

    You are here

    Home

    Biblio

    Author Title Type [ Year(Asc)]
    Filters: Author is van Imhoff, Gustaaf W  [Clear All Filters]
    2019
    Kok LMC, Bungener L, de Bock GH, Biswana A, van der Wal G, van Imhoff GW, Bellido M. Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS. Hum Cell. 2019.
    • PubMed
    • Google Scholar
    Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, de Graauw NC van der, Schouten HC, Bilgin YM, et al. Rituximab-PECC induction followed by Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019.
    • PubMed
    • Google Scholar
    2015
    Poire X, Labopin M, Cornelissen JJ, Volin L, Espiga CRichard, J Veelken H, Milpied N, Cahn J-Y, Yacoub-Agha I, van Imhoff GW, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the Acute Leukemia Working Party (ALWP) of the European group of Blood and Marrow Transplantation (EBMT). Am J Hematol. 2015.
    • PubMed
    • Google Scholar

    Disclaimer | Privacy Policy | StemBook is published by IOS Press, Copyright © 2019
    Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008–2009 by The President and Fellows of Harvard College.

    IOS Press logoHSCI logoNIH logoMIND logo


    Creative Commons License
    All content unless otherwise noted is licensed under a Creative Commons Attribution 3.0 Unported License